Jefferies initiates Altria stock with Underperform rating, cites combustibles risk

Jefferies initiated Altria (MO) with an Underperform rating and a $50.00 price target, citing concerns over accelerating volume declines in its U.S. combustibles business, consumer downtrading, and a valuation premium versus peers like British American Tobacco and Imperial Brands. This contrasts with a recent UBS upgrade to Neutral, which noted improved prospects from increased enforcement against illicit vape products, potentially stabilizing Altria's cigarette volume decline. The stock thus faces mixed analyst sentiment, balancing ongoing core business challenges with potential regulatory tailwinds.

Analysis

Altria Group (MO) faces a complex and divergent outlook, highlighted by conflicting analyst ratings. Jefferies initiated coverage with an Underperform rating and a $50 price target, citing fundamental weaknesses in the core U.S. combustibles business, including accelerated high-single-digit volume declines and consumer downtrading. The firm also notes that Altria's leadership in declining traditional oral tobacco is being offset by its position in modern oral products. This perspective is underscored by a valuation gap, with Altria trading at a calendar 2026 P/E of 11.5x, a notable premium to peers British American Tobacco (9.5x) and Imperial Brands (8.5x), who are seen as having a "firmer footing." Conversely, a recent UBS upgrade from Sell to Neutral introduces a counter-narrative, focusing on regulatory tailwinds. UBS sees improved prospects from increased enforcement against illicit vapes, supported by a 40% decline in vape exports from China to the U.S., which could stabilize cigarette volume declines. This positive regulatory momentum is further evidenced by a recent FDA and U.S. Customs seizure of illegal e-cigarettes. Meanwhile, the company maintains its commitment to capital returns, declaring a quarterly dividend of $1.02 per share, despite Jefferies' projection of slower cash return growth relative to peers.

Key Decisions for Investors

• Investors should weigh the negative fundamental outlook for Altria's core combustibles, characterized by accelerating volume declines, against the positive but uncertain impact of regulatory crackdowns on illicit vapes.
• Given Altria's valuation premium over peers like BTI and IMBBY, it is critical to assess whether potential stabilization from anti-vape enforcement justifies trading at 11.5x 2026 earnings.
• Monitor cigarette shipment volumes and market share data in upcoming quarters to verify if the regulatory actions are effectively mitigating the secular declines highlighted by Jefferies.
• For income-oriented portfolios, the $1.02 quarterly dividend remains a key consideration, but its sustainability should be viewed in light of forecasts for slower cash return growth compared to international tobacco competitors.